(Q37034397)

17 August 2017

1 reference

title

Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision (English)

1 reference

17 August 2017

0 references

0 references

1 reference

Sonya Vasto

1

1 reference

17 August 2017

Giuseppina Candore

2

1 reference

17 August 2017

Giovanni Duro

3

1 reference

17 August 2017

Domenico Lio

4

1 reference

17 August 2017

Maria Paola Grimaldi

5

1 reference

17 August 2017

Calogero Caruso

6

1 reference

17 August 2017

publication date

1 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

1735-1745

1 reference

Genetic determinants of the inflammatory response

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Cytokines in acute and chronic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Alzheimer's disease and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Developmental origins of aging in brain and blood vessels: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

ApoE: crossroads between Alzheimer's disease and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Prevalence of AD among whites: a summary by levels of severity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

A polymorphism in the complement component C1r is not associated with sporadic Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

The importance of inflammatory mechanisms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Glial cytokines in Alzheimer's disease: Review and pathogenic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Inflammation and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

The microglial "activation" continuum: from innate to adaptive responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Polymorphisms of pro-inflammatory genes and Alzheimer's disease risk: a pharmacogenomic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

NSAIDs and Alzheimer's disease: how far to generalise from trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Brain immune responses cognitive decline and dementia: relationship with phenotype expression and genetic background

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Major histocompatibility complex and sporadic Alzheimer's disease: a critical reappraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Polymorphisms in inflammatory genes and the risk of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Role of the pyrin M694V (A2080G) allele in acute myocardial infarction and longevity: a study in the Sicilian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

The M694V variant of the familial Mediterranean fever gene is associated with sporadic early-onset Alzheimer's disease in an Italian population sample

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

The pharmacogenomics of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Stress and the inflammatory response: a review of neurogenic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Human brain S100 beta and S100 beta mRNA expression increases with age: pathogenic implications for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Association between the interleukin-1alpha gene and Alzheimer's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Age-dependent association between interleukin-1A (-889) genetic polymorphism and sporadic Alzheimer's disease. A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Expression of interleukin-6 receptor (IL-6R) and gp130 mRNA in PC12 cells and sympathetic neurons: modulation by tumor necrosis factor alpha (TNF-alpha).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Characteristic localization of gp130 (the signal-transducing receptor component used in common for IL-6/IL-11/CNTF/LIF/OSM) in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Polymorphisms in the interleukin 6 and transforming growth factor beta1 gene and risk of dementia. The Rotterdam Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

21 January 2018

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

The cyclooxygenase 2 -765 C promoter allele is a protective factor for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Nicotinic receptors in human brain: topography and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

The nACHR4 594C/T polymorphism in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Polymorphisms of the CHRNA4 gene encoding the alpha4 subunit of nicotinic acetylcholine receptor as related to the oxidative DNA damage and the level of apoptotic proteins in lymphocytes of the patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Apolipoprotein E and Alzheimer's disease: the implications of progress in molecular medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Pharmacogenetics/genomics and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Genetic Determinants of 5–Lipoxygenase Transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Toward cultural competence in cancer genetic counseling and genetics education: lessons learned from Chinese-Australians

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Is immunotherapy an effective treatment for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

Apolipoprotein E Genotypic Frequencies Among Down Syndrome Patients Imply Early Unsuccessful Aging for ApoE4 Carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.12.1735

10.2217/14622416.8.12.1735

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference